Ruxolitinib inhibits cytokine production by human lung macrophages without impairing phagocytic ability

Authors: Nikola Mantov, Mathilde Zrounba, Marion Brollo, S Grassin-Delyle, Matthieu Glorion, Mélanie David, Emmanuel Naline, Philippe Devillier, Hélène Salvator

Source: Frontiers in Pharmacology, Vol 13 (2022)

Subject Terms: ruxolitinib, human macrophages, Janus kinase (2)-signal transducers and activators of transcription [JAK2-STAT5], cytokine, budenoside, Therapeutics. Pharmacology, RM1-950

File Description: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fphar.2022.896167/full; https://doaj.org/toc/1663-9812

Access URL: https://doaj.org/article/0dfecb0e5b2f4f60965ca8dbb959c020

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

New and generic drug approvals: Budenoside, inhalation suspension, Cipla. [3 tables in original article]

Source: Chemical Business NewsBase (UK), April 6, 2021, 2pp

New and generic drug approvals: Budesonide, inhalation suspension, Lupin. [1 table in original article]

Source: Chemical Business NewsBase (UK), March 29, 2021, 2pp

Salix to merge with Cosmo Technologies.

Source: Chemical Business NewsBase (UK), July 15, 2014, 2pp

AstraZeneca sells US rights to Crohn's drug to Perrigo.

Source: Chemical Business NewsBase (UK), November 30, 2015, 2pp

GSK's triple COPD combination therapy meets two co-primary endpoints in Phase III study.

Source: Chemical Business NewsBase (UK), June 21, 2016, 2pp

Astellas reports financial results of 1Q FY 2016: Japan.

Source: Chemical Business NewsBase (UK), July 29, 2016, 2pp

Deal spree continues as AstraZeneca PLC (AZN) inks $330 M pact with Johnson and Johnson (JNJ).

Source: Chemical Business NewsBase (UK), October 7, 2016, 1pp

AstraZeneca investing over EUR 135 M in Dunkerque.

Source: Chemical Business NewsBase (UK), February 1, 2016, 1pp

Puma Biotechnology presents interim results of Phase II CONTROL trial of neratinib in extended adjuvant treatment of HER2-positive early stage breast cancer at the 2017 San Antonio Breast Cancer Symposium.

Source: Chemical Business NewsBase (UK), December 7, 2017, 1pp

In brief: Cipla's antiasthma drug gets US FDA nod.

Source: Chemical Business NewsBase (UK), November 18, 2017, 1pp

UK courts rule in favour of Teva.

Source: Chemical Business NewsBase (UK), September 8, 2014, 1pp

This result is not displayed to guests.
Login for full access.